TD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)
In a report released yesterday, Ritu Baral from TD Cowen maintained a Hold rating on Spero Therapeutics (SPRO – Research Report). The company’s ...
Milestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD Cowen
Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer
Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...
GEN - Genetic Engineering and Biotechnology News10d
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Investing27d
Krystal Biotech at TD Cowen Conference: Strategic Pipeline Progress
Distributor relationships are being explored in the Middle East and North Africa. Ritu Baral, Analyst, TD Cowen: We’re going to go ahead and get started. Thank you very much for joining us for ...
Investing27d
Krystal Biotech at TD Cowen Conference: Strategic Pipeline Progress
Distributor relationships are being explored in the Middle East and North Africa. Ritu Baral, Analyst, TD Cowen: We’re going to go ahead and get started. Thank you very much for joining us for the ...